Anika Therapeutics Inc (ANIK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anika Therapeutics Inc (ANIK) has a cash flow conversion efficiency ratio of -0.036x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.85 Million) by net assets ($133.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ANIK days of operational coverage to measure how many days the company can operate on defensive assets alone.
Anika Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Anika Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Anika Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anika Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
X-Legend Entertainment Co Ltd
TW:4994
|
0.036x |
|
Adel Kalemcilik Ticaret ve Sanayi AS
IS:ADEL
|
-0.453x |
|
Muramoto Electron (Thailand) Public Company Limited
BK:METCO
|
0.113x |
|
Scottish Mortgage Investment Trust plc
LSE:SMT
|
-0.002x |
|
Information Services Group Inc
NASDAQ:III
|
-0.007x |
|
GNA Axles Limited
NSE:GNA
|
0.161x |
|
T-Robotics.Co.Ltd
KQ:117730
|
-0.078x |
|
MPC Münchmeyer Petersen Capital AG
F:MPCK
|
0.058x |
Annual Cash Flow Conversion Efficiency for Anika Therapeutics Inc (1993–2025)
The table below shows the annual cash flow conversion efficiency of Anika Therapeutics Inc from 1993 to 2025. For the full company profile with market capitalisation and key ratios, see Anika Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $143.47 Million | $11.19 Million | 0.078x | +122.26% |
| 2024-12-31 | $153.99 Million | $5.40 Million | 0.035x | +516.54% |
| 2023-12-31 | $212.26 Million | $-1.79 Million | -0.008x | -154.56% |
| 2022-12-31 | $285.56 Million | $4.41 Million | 0.015x | -47.21% |
| 2021-12-31 | $287.08 Million | $8.40 Million | 0.029x | -39.02% |
| 2020-12-31 | $272.40 Million | $13.06 Million | 0.048x | -62.62% |
| 2019-12-31 | $288.38 Million | $37.01 Million | 0.128x | -3.12% |
| 2018-12-31 | $263.61 Million | $34.92 Million | 0.132x | -14.48% |
| 2017-12-31 | $263.49 Million | $40.81 Million | 0.155x | +44.97% |
| 2016-12-31 | $222.77 Million | $23.80 Million | 0.107x | -42.33% |
| 2015-12-31 | $210.85 Million | $39.06 Million | 0.185x | -17.46% |
| 2014-12-31 | $178.10 Million | $39.98 Million | 0.224x | +20.99% |
| 2013-12-31 | $135.63 Million | $25.16 Million | 0.186x | +91.58% |
| 2012-12-31 | $108.93 Million | $10.55 Million | 0.097x | -9.79% |
| 2011-12-31 | $94.76 Million | $10.17 Million | 0.107x | +16.45% |
| 2010-12-31 | $85.19 Million | $7.85 Million | 0.092x | +144.70% |
| 2009-12-31 | $82.14 Million | $3.09 Million | 0.038x | -32.82% |
| 2008-12-31 | $60.76 Million | $3.41 Million | 0.056x | -31.39% |
| 2007-12-31 | $54.96 Million | $4.49 Million | 0.082x | +85.81% |
| 2006-12-31 | $45.49 Million | $2.00 Million | 0.044x | -74.16% |
| 2005-12-31 | $37.89 Million | $6.45 Million | 0.170x | -78.30% |
| 2004-12-31 | $30.36 Million | $23.82 Million | 0.785x | +601.34% |
| 2003-12-31 | $17.98 Million | $2.01 Million | 0.112x | +474.96% |
| 2002-12-31 | $17.06 Million | $332.03K | 0.019x | +109.07% |
| 2001-12-31 | $20.10 Million | $-4.31 Million | -0.215x | -204.37% |
| 2000-12-31 | $26.71 Million | $-1.88 Million | -0.071x | -326.50% |
| 1999-12-31 | $25.70 Million | $800.00K | 0.031x | -72.63% |
| 1998-12-31 | $29.90 Million | $3.40 Million | 0.114x | +14.59% |
| 1997-12-31 | $26.20 Million | $2.60 Million | 0.099x | +145.11% |
| 1996-12-31 | $5.00 Million | $-1.10 Million | -0.220x | +24.94% |
| 1995-12-31 | $5.80 Million | $-1.70 Million | -0.293x | +34.05% |
| 1994-12-31 | $5.40 Million | $-2.40 Million | -0.444x | -495.56% |
| 1993-12-31 | $6.70 Million | $-500.00K | -0.075x | -- |
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-op… Read more